Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Comorbidities

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    245 result(s) found for: Comorbidities. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-006161-11 Sponsor Protocol Number: RC31/20/0421 Start Date*: 2021-06-23
    Sponsor Name: Toulouse University Hospital
    Full Title: LONG -TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AND COMPARISON WITH AN UNTREATED COHORT OF CHILDREN WITH P...
    Medical condition: Prader-willi syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003410-28 Sponsor Protocol Number: CLCZ696D2302 Start Date*: 2017-06-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, exercise capacity, symptoms and safety compared to individu...
    Medical condition: Heart Failure with preserved Ejection Fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) LV (Completed) ES (Completed) FR (Completed) SK (Completed) CZ (Completed) GB (Completed) LT (Completed) AT (Completed) DK (Completed) BG (Completed) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001711-30 Sponsor Protocol Number: RIMON_R_00961 Start Date*: 2006-10-11
    Sponsor Name:sanofi aventis Groupe
    Full Title: A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fast...
    Medical condition: abdominally obese patients with impaired fasting blood glucose with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) CZ (Completed) SI (Completed) FR (Completed) NL (Prematurely Ended) NO (Completed) FI (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended) HU (Completed) SK (Completed) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001820-36 Sponsor Protocol Number: CAMG334AES01 Start Date*: 2019-08-13
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month prospective, phase IIIb, multicenter, open-label clinical trial to assess health-related quality of life (HRQoL) in patients with chronic or high-frequency episodic migraine treated with...
    Medical condition: Study of Quality of life in subjects with chronic or high-frequency episodic migraine and associated comorbidities treated with erenumab
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000930-32 Sponsor Protocol Number: SJ2021005 Start Date*: 2021-04-27
    Sponsor Name:AZ Sint-Jan Brugge-Oostende AV
    Full Title: COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2
    Medical condition: hemodialysis patients hemodialysis patients with comorbidities
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002724-33 Sponsor Protocol Number: RECHMPL19-0069 Start Date*: 2019-11-15
    Sponsor Name:University Hospital of Montpellier
    Full Title: Eosinophil-driven corticotherapy for patients hospitalized for COPD exacerbation: a double-blind, randomized, controlled trial
    Medical condition: The study population corresponds to patients hospitalized for COPD exacerbation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003923-23 Sponsor Protocol Number: 1.1 Start Date*: 2015-10-12
    Sponsor Name:Imperial College London
    Full Title: GLP-1 Receptor Agonist interVentIon for poor responders afTer bariAtric Surgery: The GRAVITAS trial
    Medical condition: TYPE 2 DIABETES MELLITUS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001680-24 Sponsor Protocol Number: ALiKE Start Date*: 2018-09-12
    Sponsor Name:Medical University of Vienna - Abteilung für Thoraxchirurgie
    Full Title: Combined low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy: a randomized prospective trial in lung transplantation
    Medical condition: Lung Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002548-12 Sponsor Protocol Number: TJB0702 Start Date*: 2007-12-17
    Sponsor Name:CHU-ULG
    Full Title: Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditionings
    Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003643-29 Sponsor Protocol Number: VAC31518COV3009 Start Date*: 2020-11-10
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older E...
    Medical condition: Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) ES (Temporarily Halted) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012476-28 Sponsor Protocol Number: BO21004 Start Date*: 2010-02-24
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb)or chlorambucil (Clb) alone ...
    Medical condition: Patients with previously untreated B-CLL with comorbidities.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) NL (Completed) RO (Completed) SK (Completed) DK (Completed) IT (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-001715-30 Sponsor Protocol Number: RIMON_R_00962 Start Date*: 2006-10-23
    Sponsor Name:sanofi aventis Groupe
    Full Title: A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with...
    Medical condition: abdominally obese patients with dyslipidemia with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) CZ (Completed) SI (Completed) NL (Completed) SE (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) SK (Completed) HU (Completed) GR (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005896-12 Sponsor Protocol Number: CBYL719F12401 Start Date*: 2021-10-20
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (E...
    Medical condition: PIK3CA-related overgrowth spectrum (PROS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10081236 PIK3CA related overgrowth spectrum PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002207-17 Sponsor Protocol Number: D-PLEX-302 Start Date*: 2020-07-14
    Sponsor Name:PolyPid Ltd.
    Full Title: A Phase III, Prospective, Multinational, Multicenter, Randomized, Parallel Controlled, Two arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly with the ...
    Medical condition: Prevention of Post-Cardiac Surgery Sternal Infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10078408 Surgical site infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003486-17 Sponsor Protocol Number: 9-VPH-MVIH Start Date*: 2020-02-11
    Sponsor Name:CARMEN HIDALGO TENORIO
    Full Title: Immunogenicity and safety of a 9-valent human papillomavirus vaccine in HIV-positive women
    Medical condition: New infection and lesions of papillomavirus in HIV-infected women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018369-48 Sponsor Protocol Number: CASTIP3 Start Date*: 2011-03-10
    Sponsor Name:Medizinische Universität Wien
    Full Title: Der Einfluss von Adalimumab auf kardiovaskuläre und metabolische Risikofaktoren in der Therapie von Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris im Vergleich zu einer Standardtherap...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-006127-34 Sponsor Protocol Number: 1.3 Start Date*: 2021-09-17
    Sponsor Name:Verein zur Förderung der Wissenschaft und Forschung an der 1.Med. Abteilung der Krankenanstalt Rudolfstiftung
    Full Title: Empagliflozin as potential treatment option for postprandial hyperinsulinemic hypoglycaemia after bariatric surgery – a pilot study
    Medical condition: Postprandial hyperinsulinemic hypoglycaemia (PHH) typically occurs years after bariatric surgery and one to three hours after a carbohydrate-rich meal. It is caused by rapid gastric emptying of und...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001606-33 Sponsor Protocol Number: HIACO-19 Start Date*: 2020-04-07
    Sponsor Name:Instituto Investigación Sanitario Biocruces Bizkaia
    Full Title: Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection.
    Medical condition: COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001639-38 Sponsor Protocol Number: MDS/2013 Start Date*: 2016-12-06
    Sponsor Name:1st Dep. of Medicine, General University Hospital (VFN) in Prague
    Full Title: Contribution to verify the effectiveness of adding granulocyte stimulating factor (G-CSF) to therapy 5 - Azacitidine patients with the high risk Myelodysplastic syndrome.
    Medical condition: Patients with the diagnosis:HR-MDS, AML less than 30% myeloblasts and CMML II, who will be treated with AZA or AZA + G-CSF.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000825-11 Sponsor Protocol Number: P160914J Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Lithium effect in patients with Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 haploinsuffisance): pilot study.
    Medical condition: Autistic Spectrum Disorder and Phelan-McDermid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 10:55:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA